CrownBio and Hubrecht Organoid Technology Announce a Strategic Partnership, including Exclusive License to Provide Oncology Organoid-Based Preclinical Drug Development and Validation Services

NEXT STORY
Genkyotex Reverse Stock Split Takes Effect
PREV STORY
GILEAD AND GALAPAGOS REPORT UPDATED SAFETY INFORMATION FOR FILGOTINIB IN RHEUMATOID ARTHRITIS (RA)
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Progenics Pharmaceuticals Announces Presentations on AZEDRA® (iobenguane I 131) and its Prostate Cancer Programs at the 30th Annual Congress of the European Association of Nuclear Medicine

NEW YORK, Oct. 16, 2017 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology ...

author_avatar
NASDAQ Market News

Protalix BioTherapeutics Expands Partnership with Chiesi Farmaceutici to Include Exclusive U.S. Rights for the Development and Commercialization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease

Protalix to receive $25 million upfront, an additional up to $20 million in development ...

author_avatar
NASDAQ Market News

Athenex Announces Initiation of an Oral Eribulin Investigational New Drug Development Program for Oncology Indications

Athenex has developed a novel synthetic method for Eribulin with an excellent purity profileAthenex ...

author_avatar
NASDAQ Market News